Upstream Bio (UPB) EBITDA (2023 - 2026)

Upstream Bio's EBITDA history runs 4 years deep, the most recent figure standing at -$43.6 million for Q1 2026.

• On a quarterly basis, EBITDA fell 36.24% year-over-year to -$43.6 million in Q1 2026; TTM through Mar 2026 was -$172.0 million, a 81.46% decrease from a year earlier, with the FY2025 full-year figure at -$160.4 million, down 106.21% from the prior year.
• EBITDA grew to -$43.6 million in Q1 2026 per UPB's latest filing, from -$46.2 million in the prior quarter.
• Across five years, EBITDA topped out at -$9.4 million in Q3 2023 and bottomed at -$46.2 million in Q4 2025.
• The 4-year median for EBITDA is -$26.3 million (2024), against an average of -$27.8 million.
• Across the five-year window, EBITDA tumbled 152.83% in 2025 and plunged 36.24% in 2026, its largest moves.
• Year by year, EBITDA stood at -$14.3 million in 2023, then sank by 83.66% to -$26.3 million in 2024, then plunged by 75.42% to -$46.2 million in 2025, then gained by 5.53% to -$43.6 million in 2026.
• Per Business Quant, the three latest UPB EBITDA figures stand at -$43.6 million (Q1 2026), -$46.2 million (Q4 2025), and -$37.8 million (Q3 2025).